Table 3 Distribution of clinical parameters according to the ERα/PI3K expression
Variable | ERα/PI3K ≤9, no. (%) | ERα/PI3K >9, no. (%) | P | |
|---|---|---|---|---|
Age groups | <50 years | 75 (28.7) | 36 (23.1) | 0.206 |
>50 years | 186 (71.3) | 120 (76.9) | ||
T. size | <2 cm | 157 (60.2) | 84 (53.8) | 0.207 |
>2 cm | 104 (39.8) | 72 (46.2) | ||
LN invasion | No | 115 (44.1) | 60 (38.5) | 0.262 |
Yes | 146 (55.9) | 96 (61.5) | ||
SBR grade | Gr 1 | 54 (20.7) | 25 (16.0) | 0.069 |
Gr 2 | 130 (49.8) | 68 (43.6) | ||
Gr 3 | 77 (29.5) | 63 (40.4) | ||
ER status | Negative | 31 (11.9) | 22 (14.1) | 0.509 |
Positive | 230 (88.1) | 134 (85.9) | ||
PR status | Negative | 60 (23.0) | 45 (28.8) | 0.182 |
Positive | 201 (77.0) | 111 (71.2) | ||
HER2 status | Negative | 238 (93.0) | 144 (92.3) | 0.802 |
Positive | 18 (7.0) | 12 (7.7) | ||
Breast Cancer subtype | Luminal A | 155 (59.4) | 77 (49.4) | 0.249 |
Luminal B | 75 (28.7) | 57 (36.5) | ||
HER2 rich | 6 (2.3) | 5 (3.2) | ||
TNBC | 25 (9.6) | 17 (10.9) | ||
Type of adjuvant hormonal | Tamoxifen | 97 (57.1) | 65 (49.2) | 0.151 |
AI | 129 (42.9) | 67 (50.8) | ||